Surgical Resutls of Stage IV Non-Small Cell Lung Cancer(NSCLC)

제4기 비소세포성 폐암 환자의 수술 결과

  • 맹대현 (연세대학교 의과대학 흉부외과학교실) ;
  • 정경영 (연세대학교 의과대학 흉부외과학교실) ;
  • 김길동 (연세대학교 의과대학 흉부외과학교실) ;
  • 김도균 (연세대학교 의과대학 흉부외과학교실)
  • Published : 2000.04.01

Abstract

Background: The surgical indications of stage IV non-small cell lung cancer(NSCLC) are extremely limited with its controversial results. We analyzed the surgical results and survival in selected patients with resectable stage IV NSCLC. Material and Method: We reviewed the medical records of 21 patients who underwent operation for stage IV NSCLC from Jan. 1992 to Sep. 1999. Result: The mean age of patients was 55.6 years(range: 35 to 78). Sixteen were men and 5 were women. Tissue types were squamous cell carcinoma in 10(45.5%), adenocarcinoma in 9(40.9%), large cell carcinoma in 1 and carcinosarcoma in 1. Distant metastatic lesions were ipsilateral other lobe of lung in 18, brain in 2 and adrenal gland in 1. Pneumonectomy was performed in 16 patients, bilobectomy in 3, and lobectomy in 2 who underwent previous operatin for brain metastasis. Mean follow-up duration was 21.2$\pm$17.7 months. During follow-up period, 13 patients died. Three-and 5-year survival of patients were 38.0% and 19.0%, the median survival time was 19.1$\pm$7.8 months. In the group with ipsilateral pulonary metastasis(PM, n=18), 3- and 5-year survival of patients with N0 and N1(n=9) disease were 64.8% and 32.4%, median survival time was 55.3$\pm$27.2 months. Three-year survival of patients with N2(n=9) disease was 11.1%, median survival time was 10.6$\pm$0.3 months. The survival of N0 and N1 disease group was significantly better than that of N2 disease group(p=0.042). Also the disease free survival of N0 and N1 was significantly better than that of N2 disease in overall group(53.3 months vs 12.1 months, p=0.036) and ipsilateral PM group(63.4 months vs 8.8 months, p=0.001). Conclusion: We suggest that surgical treatment is worthful modality in well selected patients with stage IV NHSCLC especially with ipsilateral PM and N0 or N1 disease,. Nevertheless our study indicate questions that will need to be experienced further in larger studies.

Keywords

References

  1. Thorax v.51 Factors affecting long term survival following resection for lung cancer. Al-Kattan M;Sepsas E;Townsend ER;Fountain SW.
  2. J Thorac Cardiovasc Surg v.1103 Resection of brain metastasis from non-small cell lung cancer: Results of therapy. Burt M.;Wronski M.;Arbit E;Gallicich JH.
  3. Ann Thorac Surg v.42 Surgical application to lung cancer with cerebral metastasis: 25year experience. MacGillian DJ;Duvenory C;Malik G(et al.)
  4. TH. Thoracic oncology Surgery for non-small cell lung cancer: Roth JA, Ruckdeschel JC, Weisenburger Ginsberg RJ;Goldberg M;Waters PF
  5. Chest v.112 Implication of staging in lung cancer. Naruke T;Tsuchiya T;Kondo H;Asamura H;Nakayama H
  6. 제29차 대한흉부외과학회 추계학술대회 초록집 v.35 폐암의 새 병기 분류법의 평가 조재일;박종호;백희종;심영목
  7. J Thorac Cardiovasc Surg v.97 Carcinoma of the lung: evaluation of satellite nodules as a factor influencing prognosis after resection. Deslaurier J;Brisson J;Cattier R(et al)
  8. Ann Thorac Surg v.68 Evaluation of TNM classification for lung carcinoma with ipsilateral intrapulmonary metastasis. Okada M;Tsubora N;Yoshimura M;Miyamoto Y;Nakai R.
  9. Ann Thorac Surg v.61 Excellent Survival in a subgroup of patients with intrapulmonary metastasis of lung cancer. Nakajima J;Furuse A;Oka T;Kohno, T;Ohtsuka T.
  10. Ann Thorac Surg v.64 Postoperative prognosis in patients with non-small cell lung cancer with synchronous ipsilateral intrapulmonary metastasis. Yoshino I;Nakanishi R;Osaki T(et al.)
  11. Eur J Cardiothorac Surg v.12 Prognosis of ipsilateral metastases in resected nonsmall cell lung cancer. Fukuse T;Hirata T;Tanaka F;Yanagihara K;Hitomi S.;Wada H.
  12. N Eng J Med. v.330 A randomized trial comparing preoperatic chomotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. Rosell R;Gomez-Codina J;Camp C(et al)